A Cardiomiopatia Chagásica Crônica (CCC) é uma cardiopatia dilatada inflamatória caracterizada por remodelamento cardíaco, uma miocardite rica em células T e macrófagos, hipertrofia e fibrose. Essa acomete 30% dos pacientes infectados com Trypanossoma cruzi (T. cruzi). Os pacientes com CCC apresentam uma pior sobrevida e prognóstico quando comparados com pacientes portadores de cardiomiopatia de etiologia não inflamatória, como a cardiomiopatia dilatada idiopática (CDI). No processo de remodelamento cardíaco, ocorre uma reestruturação da matriz extracelular (MEC), mediada em grande parte por proteínas como as enzimas proteolíticas, metaloproteinases da matriz (MMPs) e seus inibidores específicos (TIMPs), sendo que a alteração e/ou atividade de algumas dessas enzimas em particular está relacionado com as doenças cardiovasculares. Dentro deste contexto, a hipótese deste trabalho é a de que o perfil da expressão e atividade das MMPs e de seus inibidores TIMPs na CCC será distinto do encontrado na CDI. Foi avaliado por qRT-PCR a expressão gênica e por \"Western blotting\" a expressão proteica das MMPs: -1, -2, -3, -8, -9, -12-13 e EMMPRIN e dos seguintes inibidores TIMPs: -1, -2, -3, -4 e RECK e atividade da MMP-2 e -9 por zimografia, em amostras de miocárdio (ventrículo esquerdo) de pacientes com CCC, pacientes com CDI e doadores de órgãos, obtidos durante o procedimento de transplante. Embora algumas das alterações da expressão das MMPs, TIMPs, e RECK tenham sido compartilhadas com a CDI, observamos que os pacientes com CCC apresentam o aumento da atividade da MMP-2 e MMP-9 e aumento exclusivo da proteína MMP-9. Analisamos através da razão entre a atividade da MMP-2 e MMP-9 com a expressão proteica dos inibidores TIMPs e RECK, observamos o aumento da atividade da MMP-2 e MMP-9 e a diminuição dos TIMPs: -1, -2, -3 e -4 e TIMPs -1, -2 e -3, respectivamente em pacientes com CCC, ocasionando um desequilíbrio entre sua ativação e inibição o que contribui com o remodelamento do miocárdio. Também foi avaliado a fração de colágeno intersticial por Picrosirius Red, observamos que o aumento de colágeno em pacientes com CCC e CDI, o que indica que o aumento da atividade da MMP-2 e MMP-9 está modulando a síntese, conformação e organização do colágeno, contribuindo com a fibrose em pacientes com CCC. Com objetivo de verificar se estas MMPs e seus inibidores estariam sob-regulação pós-transcricional, realizamos análise in silico e identificamos 8 microRNAs (miR): miR-21, miR-29- 5p, miR-146a-5p, miR-155-5p, miR-188-5p, miR-214-3p, miR-491-5p e miR885-5p e analisamos suas expressões por qRT-PCR, mas não observamos correlação com as MMPs e seus inibidores, sugerindo que estas proteínas não estão sob regulação pós-transcricional pelos miRs analisados. Em conjunto, nossos resultados sugerem que a expressão diferencial de MMPs e seus inibidores TIMPs estudados contribuem com a fibrose, remodelamento do miocárdio e disfunção cardíaca, observado em pacientes com CCC. Desta forma, este trabalho pode ajudar na elucidação dos mecanismos de desenvolvimento da patogênese da doença de Chagas / Chronic Chagas Cardiomyopathy (CCC) is an inflammatory dilated cardiomyopathy characterized by cardiac remodeling, a myocarditis rich in T cells and macrophages, hypertrophy and fibrosis. This affects 30% of patients infected with Trypanosoma cruzi (T. cruzi). Patients with CCC have a poorer prognosis and survival when compared with cardiomyopathy patients with non-inflammatory etiology, such as idiopathic dilated cardiomyopathy (IDC). In cardiac remodeling process, there is a restructuring of the extracellular matrix (ECM), largely mediated by proteins such as proteolytic enzymes, matrix metalloproteinases (MMPs) and their specific inhibitors (TIMPs). The alteration and/or activity of some these particular enzymes is associated with cardiovascular disease. Taking this into account, the hypothesis of this study is that the expression profile and activity of MMPs and their TIMPs inhibitors in the CCC will be different from those found in IDC. The gene expression was evaluated by qRT-PCR, the MMP protein expression: -1, -2, -3, -8, -9, -12-13 and EMMPRIN by \"Western blotting\" and the following TIMP inhibitors: -1 , -2, -3, -4 and RECK and MMP-2 and -9 activity by zymography, in myocardial samples (left ventricle) of CCC and IDC patients and organ donors (Control) obtained upon transplantation. Although some of these changes in the expression of MMPs, TIMPs and RECK were shared with the IDC, we observed that patients with CCC have increased MMP-2 and MMP-9 activity and exclusive increase in MMP-9 protein. Through the ratio of MMP-2 and MMP-9 activity with protein expression of TIMPs and RECK inhibitors, we found that the increase in MMP-2 and MMP-9 activity and the decrease in TIMP: -1, -2, -3, and -4 and TIMP -1, -2 and -3, respectively, in myocardial samples of CCC patients causes an imbalance in their activation and inhibition, contributing to the myocardium remodeling. The fraction of interstitial collagen as stained by Picrosirius Red, indicates increase in collagen in patients with CCC and IDC, indicating that the increase of MMP-2 and MMP-9 activity is modulating the synthesis and conformation of collagen organization, contribute to fibrosis in patients with CCC. Aiming to verify whether these MMPs and their inhibitors would be under post-transcriptional regulation, we performed in silico analysis and it was identified 8 microRNAs (miR): miR-21, miR-29-5p, miR-146a-5p, miR-155-5p , miR-188-5p, miR-214-3p, miR-491-5p and miR885-5p, but no correlation was found with the MMPs and their inhibitors, suggesting that these proteins are not under post-transcriptional regulation by miRs analyzed. Together our results suggest that differential expression of MMPs and their TIMPs inhibitors studied contribute to fibrosis, myocardial remodeling and cardiac dysfunction observed in patients with CCC. Thus, this work may help in elucidating the development of mechanisms of the pathogenesis of Chagas disease

Submitted by Andreia Grizzo null (grizzo.andreia@gmail.com) on 2017-09-12T01:10:55Z No. of bitstreams: 1 MESTRADO 11_09.pdf: 2257201 bytes, checksum: 16dbde33ba443c1645e05a71110959e4 (MD5) / Approved for entry into archive by Monique Sasaki (sayumi_sasaki@hotmail.com) on 2017-09-12T17:39:02Z (GMT) No. of bitstreams: 1 grizzo_a_me_bot.pdf: 2261723 bytes, checksum: 6c5484268fa35ad436d271ab196ecc86 (MD5) / Made available in DSpace on 2017-09-12T17:39:02Z (GMT). No. of bitstreams: 1 grizzo_a_me_bot.pdf: 2261723 bytes, checksum: 6c5484268fa35ad436d271ab196ecc86 (MD5) Previous issue date: 2017-06-09 / INTRODUÇÃO: Cardiomiopatia é uma alteração do miocárdio em que o músculo do coração é estruturalmente e/ou funcionalmente anormal, na ausência de doença de artérias coronárias, hipertensão arterial, doenças valvares e cardiopatias congênitas. A Cardiomiopatia dilatada é o tipo mais frequente na faixa etária pediátrica, caracterizando-se por apresentar dilatação do ventrículo esquerdo com disfunção sistólica na ausência de condições de carga anormais, com incidência de aproximadamente 0,57 casos/100.000 habitantes ao ano e maior prevalência no sexo masculino. Apresenta curso progressivo, elevado custo de tratamento e é a principal causa de transplante cardíaco em pediatria. Em cinco anos de acompanhamento, aproximadamente 2,5% evoluem com morte súbita e 29% tem indicação de transplante cardíaco. A etiologia ao diagnóstico é pouco conhecida, permanecendo a causa idiopática como a mais frequente, incluindo entre elas causas genéticas e familiares não identificadas, seguida das miocardites. O diagnóstico é baseado em sintomas de insuficiência cardíaca congestiva (ICC) ou alterações em exames de imagem na ausência de sinais de ICC. O exame complementar mais importante é o ecocardiograma com doppler colorido que permite a avaliação da dilatação do VE, fração de ejeção do VE (FEVE) <55% e/ou hipocinesia de VE. O tratamento na fase aguda da doença deve ser baseado na classificação hemodinâmica, sendo utilizados inibidores da enzima de conversão da angiotensina (IECA), betabloqueadores, diuréticos e drogas inotrópicas positivas, principalmente nos casos de descompensação clínica mais grave. OBJETIVO: Padronizar um protocolo para o diagnóstico e tratamento da cardiomiopatia dilatada na faixa etária pediátrica de acordo com nossa realidade institucional, baseado nas melhores evidências disponíveis na literatura. METODOLOGIA:Estudo de revisão da literatura realizado nas principais fontes: Pubmed, Embase, LILACS, Cochrane e Uptodate; priorizando os publicados nos últimos 10 anos. RESULTADO:Há poucos estudos sobre o diagnóstico e tratamento de cardiomiopatia dilatada em pediatria com bom nível de evidência. Um algoritmo para o diagnóstico e tratamento baseado nas melhores evidências disponíveis na literatura e nas condições existentes em nosso serviço foi construído e será disponibilizado junto aos médicos responsáveis pelo atendimento aos pacientes pediátricos com diagnóstico de cardiomiopatia dilatada. CONCLUSÃO: A utilização de protocolo poderá proporcionar a otimização dos recursos hospitalares utilizados para o diagnóstico e o tratamento de cardiomiopatia dilatada com aumento do diagnóstico precoce e instituição do tratamento mais adequado. / INTRODUTION: Cardiomyopathy is a myocardial disorder in which the heart muscle is structurally and/or functionally abnormal, in the absence of coronary artery disease, arterial hypertension, valvular heart disease and congenital heart disease. Dilated Cardiomyopathy is the most common type in the pediatric age group, characterized by a dilation of the left ventricle with systolic dysfunction in the absence of abnormal loading conditions, with an incidence of approximately 0.57 cases/100,000 inhabitants per year and higher prevalence in the male gender. It is a progressive disease, with a high cost of treatment and is the major cause of heart transplantation in pediatrics. In five years of following up, nearly 2.5% evolve with sudden death and 29% have an indication for heart transplantation. The etiology to diagnosis is little known, and the idiopathic cause remains the most frequent one, including among them unidentified genetic and familial causes, followed by myocarditis. The diagnosis is based on symptoms of congestive heart failure (HF), or changes in imaging tests, in the absence of signs of HF. The most important complementary exam is the color Doppler echocardiography, which allows an assessment of the LV dilation, Left Ventricular ejection fraction (LVFE) < 55% and/or LV hypokinesis. Treatment in the acute phase of the disease should be based on hemodynamic classification, using angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics and positive inotropic drugs, especially in cases of more severe clinical decompensation. OBJECTIVE: To standardize a protocol for dilated cardiomyopathy diagnosis and treatment in the pediatric age group according to our institutional reality based on the best evidence available in the literature. METHODOLOGY:A revision of the literature performed in the main sources: Pubmed, Embase, LILACS, Cochrane and Uptodate; prioritizing those published in the last 10 years. RESULT:There are a few studies on dilated cardiomyopathy diagnosis and treatment in pediatrics with good level of evidence. An algorithm for diagnosis and treatment based on the best evidence available in the literature and in the conditions existing in our service was built and will be make available to physicians in charge of the care of pediatric patients diagnosed with dilated cardiomyopathy. CONCLUSION: The use of protocol may provide the optimization of hospital resources used for the diagnosis and treatment of dilated cardiomyopathy with increased early diagnosis and the institution of the most appropriate treatment.

A Cardiomiopatia Chagásica Crônica (CCC) é uma cardiopatia dilatada inflamatória caracterizada por remodelamento cardíaco, uma miocardite rica em células T e macrófagos, hipertrofia e fibrose. Essa acomete 30% dos pacientes infectados com Trypanossoma cruzi (T. cruzi). Os pacientes com CCC apresentam uma pior sobrevida e prognóstico quando comparados com pacientes portadores de cardiomiopatia de etiologia não inflamatória, como a cardiomiopatia dilatada idiopática (CDI). No processo de remodelamento cardíaco, ocorre uma reestruturação da matriz extracelular (MEC), mediada em grande parte por proteínas como as enzimas proteolíticas, metaloproteinases da matriz (MMPs) e seus inibidores específicos (TIMPs), sendo que a alteração e/ou atividade de algumas dessas enzimas em particular está relacionado com as doenças cardiovasculares. Dentro deste contexto, a hipótese deste trabalho é a de que o perfil da expressão e atividade das MMPs e de seus inibidores TIMPs na CCC será distinto do encontrado na CDI. Foi avaliado por qRT-PCR a expressão gênica e por \"Western blotting\" a expressão proteica das MMPs: -1, -2, -3, -8, -9, -12-13 e EMMPRIN e dos seguintes inibidores TIMPs: -1, -2, -3, -4 e RECK e atividade da MMP-2 e -9 por zimografia, em amostras de miocárdio (ventrículo esquerdo) de pacientes com CCC, pacientes com CDI e doadores de órgãos, obtidos durante o procedimento de transplante. Embora algumas das alterações da expressão das MMPs, TIMPs, e RECK tenham sido compartilhadas com a CDI, observamos que os pacientes com CCC apresentam o aumento da atividade da MMP-2 e MMP-9 e aumento exclusivo da proteína MMP-9. Analisamos através da razão entre a atividade da MMP-2 e MMP-9 com a expressão proteica dos inibidores TIMPs e RECK, observamos o aumento da atividade da MMP-2 e MMP-9 e a diminuição dos TIMPs: -1, -2, -3 e -4 e TIMPs -1, -2 e -3, respectivamente em pacientes com CCC, ocasionando um desequilíbrio entre sua ativação e inibição o que contribui com o remodelamento do miocárdio. Também foi avaliado a fração de colágeno intersticial por Picrosirius Red, observamos que o aumento de colágeno em pacientes com CCC e CDI, o que indica que o aumento da atividade da MMP-2 e MMP-9 está modulando a síntese, conformação e organização do colágeno, contribuindo com a fibrose em pacientes com CCC. Com objetivo de verificar se estas MMPs e seus inibidores estariam sob-regulação pós-transcricional, realizamos análise in silico e identificamos 8 microRNAs (miR): miR-21, miR-29- 5p, miR-146a-5p, miR-155-5p, miR-188-5p, miR-214-3p, miR-491-5p e miR885-5p e analisamos suas expressões por qRT-PCR, mas não observamos correlação com as MMPs e seus inibidores, sugerindo que estas proteínas não estão sob regulação pós-transcricional pelos miRs analisados. Em conjunto, nossos resultados sugerem que a expressão diferencial de MMPs e seus inibidores TIMPs estudados contribuem com a fibrose, remodelamento do miocárdio e disfunção cardíaca, observado em pacientes com CCC. Desta forma, este trabalho pode ajudar na elucidação dos mecanismos de desenvolvimento da patogênese da doença de Chagas / Chronic Chagas Cardiomyopathy (CCC) is an inflammatory dilated cardiomyopathy characterized by cardiac remodeling, a myocarditis rich in T cells and macrophages, hypertrophy and fibrosis. This affects 30% of patients infected with Trypanosoma cruzi (T. cruzi). Patients with CCC have a poorer prognosis and survival when compared with cardiomyopathy patients with non-inflammatory etiology, such as idiopathic dilated cardiomyopathy (IDC). In cardiac remodeling process, there is a restructuring of the extracellular matrix (ECM), largely mediated by proteins such as proteolytic enzymes, matrix metalloproteinases (MMPs) and their specific inhibitors (TIMPs). The alteration and/or activity of some these particular enzymes is associated with cardiovascular disease. Taking this into account, the hypothesis of this study is that the expression profile and activity of MMPs and their TIMPs inhibitors in the CCC will be different from those found in IDC. The gene expression was evaluated by qRT-PCR, the MMP protein expression: -1, -2, -3, -8, -9, -12-13 and EMMPRIN by \"Western blotting\" and the following TIMP inhibitors: -1 , -2, -3, -4 and RECK and MMP-2 and -9 activity by zymography, in myocardial samples (left ventricle) of CCC and IDC patients and organ donors (Control) obtained upon transplantation. Although some of these changes in the expression of MMPs, TIMPs and RECK were shared with the IDC, we observed that patients with CCC have increased MMP-2 and MMP-9 activity and exclusive increase in MMP-9 protein. Through the ratio of MMP-2 and MMP-9 activity with protein expression of TIMPs and RECK inhibitors, we found that the increase in MMP-2 and MMP-9 activity and the decrease in TIMP: -1, -2, -3, and -4 and TIMP -1, -2 and -3, respectively, in myocardial samples of CCC patients causes an imbalance in their activation and inhibition, contributing to the myocardium remodeling. The fraction of interstitial collagen as stained by Picrosirius Red, indicates increase in collagen in patients with CCC and IDC, indicating that the increase of MMP-2 and MMP-9 activity is modulating the synthesis and conformation of collagen organization, contribute to fibrosis in patients with CCC. Aiming to verify whether these MMPs and their inhibitors would be under post-transcriptional regulation, we performed in silico analysis and it was identified 8 microRNAs (miR): miR-21, miR-29-5p, miR-146a-5p, miR-155-5p , miR-188-5p, miR-214-3p, miR-491-5p and miR885-5p, but no correlation was found with the MMPs and their inhibitors, suggesting that these proteins are not under post-transcriptional regulation by miRs analyzed. Together our results suggest that differential expression of MMPs and their TIMPs inhibitors studied contribute to fibrosis, myocardial remodeling and cardiac dysfunction observed in patients with CCC. Thus, this work may help in elucidating the development of mechanisms of the pathogenesis of Chagas disease

Le remodelage myocardique est une réponse du myocarde à une altération des contraintes pariétales générée par une agression aiguë (ischémie myocardique) ou chronique (surcharge en pression, surcharge en volume, anomalie métabolique). En effet, le cœur est un organe capable de modifier en fonction de ses conditions de travail l’expression de ses fonctions moléculaires et cellulaires pour aboutir à des changements de taille,de morphologie et de fonction. Le remodelage myocardique est un mécanisme adaptatif initialement bénéfique, car en modifiant sa géométrie, le ventricule gauche s’adapte aux modifications de stress pariétal et préserve le volume d’éjection systolique. / Not transmitted

Hypertrophic cardiomyopathy (HCM) is a primary disease of the myocardium. 4-11% of HCM is caused by mutations in cardiac troponin T (cTnT) and 65% of them are within the tropomyosin (TM)-binding TNT1 domain. Two of the known mutational hotspots within TNT1 are in the N and C-terminal domains. Unlike the N-terminal domain; no high-resolution structure exists for the highly conserved C-terminal domain limiting both our ability to understand the functional role of this extended domain in myofilament activation and molecular mechanism(s) of HCM. The Δ160E mutation is an in-frame deletion of a glutamic acid residue at position 160 of cTnT. This TNT1 C-terminal mutation is associated with an especially poor prognosis. The Δ160E mutation is located in a putative "hinge region" immediately adjacent to the unstructured flexible linker connecting the TM-binding TNT1 domain to the Ca²⁺-sensitive TNT2 domain. Unwinding of this α-helical hinge may provide the flexibility necessary for thin filament function. Previous regulated in vitro motility assay (R-IVM) data showed mutation-induced impairment of weak actomyosin binding. Thus, we hypothesized that the Δ160E mutation repositions the flexible linker which impairs weak electrostatic binding and ultimately leads to severe cardiac remodeling. The goal of our studies is two-fold: 1) to gain high-resolution insight into the position of the cTnT linker with respect to the C-terminus of TM, and 2) to identify Δ160E-induced positional changes using Fluorescence Resonance Energy Transfer (FRET) in a fully reconstituted thin filament. To this end, residues in the middle and distal regions of the cTnT linker were sequentially cysteine-substituted (A168C, A177C, A192C and S198C) and labeled with the energy donor IAEDANS. The energy acceptor, DABMI was attached to cysteine 190 (C190) in the C-terminal region of TM and FRET measurements were obtained in the presence and absence of Ca²⁺ and myosin subfragment 1 (S1). An all-atom thin filament model in the Ca²⁺–on state was employed to predict the pathogenic effects of the Δ160E mutation on the structure and the dynamics of the cTnT linker region. Our data suggest that the linker domain runs alongside the C-terminus of TM and is differentially repositioned by calcium, myosin and the Δ160E mutation. The Δ160E mutation moves the linker closer to the C-terminus of TM. The in silico model supported this finding and demonstrated a mutation-induced decrease in linker flexibility. Moreover, the model predicted a pathogenic change in the orientation of the middle region of the linker and in the position of the Ca²⁺-sensitive TNT2 domain and the TM-binding TNT1 domain in response to Δ160E mutation. Collectively, our findings suggest that the Δ160E mutation-induced changes in the structure, position and dynamics of the linker region cause steric blocking of weak myosin binding sites on actin and subsequent impairment of contraction and disruption of sarcomeric integrity. These studies, for the first time, provided information regarding the role of the extended linker in both myofilament activation and disease.

Both hypertrophied and failing hearts are characterised by pathological left ventricular (LV) remodelling, impaired myocardial energy status and alteration in substrate metabolism. Cardiac magnetic resonance imaging (CMR) and magnetic resonance spectroscopy (MRS) are powerful tools in the characterisation of these disease conditions. More recent techniques have allowed assessment of myocardial steatosis using ¹H-MRS and tissue oxygenation using blood oxygen level dependent (BOLD) CMR. In hypertrophy and heart failure, studies on steatosis and the relationship with other parameters such as myocardial function and fibrosis, especially in humans are limited. I therefore investigated the presence of steatosis in severe aortic stenosis (AS) and dilated cardiomyopathy (DCM), and further assessed its relation to contractile function. This study found that myocardial triglyceride (TG) content is increased in both symptomatic and asymptomatic AS patients (lipid/water ratio 0.89±0.42% in symptomatic AS; 0.75±0.36% in asymptomatic AS vs. controls 0.45±0.17%, both p<0.05) and DCM patients (lipid/ratio 0.64±0.44% vs. controls 0.40±0.13%, p=0.03). Circumferential strain was lower in both AS (-16.4±2.5% in symptomatic AS; -18.9±2.9% in asymptomatic AS vs. controls 20.7±2.0%, both p<0.05) and DCM patients (-12.3±3.4% vs. controls -20.9±1.7%, p<0.001). In AS, myocardial contractility is related to the degree of steatosis, and were both reversible following aortic valve replacement (AVR), lipid/water ratio 0.92±0.41% vs. pre AVR 0.45±0.17%, p=0.04 and circumferential strain -17.2±2.0% vs. pre AVR -19.5±3.2%, p=0.04. A novel finding of this study was significant correlation of MRS-measured TG content with histological staining of TG of the myocardium, taken from endomyocardial biopsy during AVR. In DCM, myocardial TG was independently associated with LV dilatation and correlated significantly with hepatic TG, which suggests that both cardiac and hepatic steatosis might be a common feature in the failing heart. Additionally, although the hypertrophied heart is characterised by impaired perfusion, it is unknown if this is severe enough to translate into tissue deoxygenation and ischaemia. I assessed this by using adenosine vasodilator stress test and BOLD-CMR in patients with severe AS. It was found that AS patients had reduced perfusion (myocardial perfusion reserve index-MPRI 1.0±0.3 vs. controls 1.7±0.3, p<0.001), and blunted tissue oxygenation (blood-oxygen level dependent-BOLD signal intensity-SI change 4.8±9.6% vs. controls 18.2±11.6%, p=0.001) during stress. Importantly, there was a substantial improvement in perfusion and oxygenation towards normal after AVR, MPRI 1.5±0.4, p=0.005 vs. pre AVR and BOLD SI change 16.4±7.0%, p=0.014 vs. pre AVR. Overall, the work in this thesis supports the powerful role of CMR in assessing LV function and elucidating metabolic mechanisms in the hypertrophied and failing heart.

Thesis (PhD)--Stellenbosch University, 2014. / ENGLISH ABSTRACT: Left ventricular hypertrophy (LVH) is a major risk factor for cardiovascular morbidity and mortality, and is a feature of common diseases, such as hypertension and diabetes. It is therefore vital to understand the underlying mechanisms influencing its development. However, investigating the mechanisms underlying LVH in such complex disorders can be challenging. For this reason, many researchers have focused their attention on the autosomal dominant cardiac muscle disorder, hypertrophic cardiomyopathy (HCM), since it is considered a model disease in which to study the causal molecular factors underlying isolated cardiac hypertrophy. HCM is a heterogeneous disease that manifests with various phenotypes and clinical symptoms, even in families with the same genetic defects, suggesting that additional factors contribute to the disease phenotype. Despite the identification of several HCM-causing genes, the genetic factors that modify the extent of hypertrophy in HCM patients remain relatively unknown. The gene encoding the sarcomeric protein, cardiac myosin binding protein C, cMyBPC (MyBPC3) is one of the most frequently implicated genes in HCM. Identification of proteins that interact with cMyBPC has led to improved insights into the function of this protein and its role in cardiac hypertrophy. However, very little is known about another member of the myosin binding protein family, myosin binding protein H (MyBPH). Given the sequence homology and similarity in structure between cMyBPC and MyBPH, we propose that MyBPH, like cMyBPC, may play a critical role in the structure and functionality of the cardiac sarcomere and could therefore be involved in HCM pathogenesis. The present study aimed to identify MyBPH-interacting proteins by using yeast two-hybrid (Y2H) analysis and to verify these interactions using three-dimensional (3D) co-localisation and co-immunoprecipitation (Co-IP) analyses. We further hypothesized that both MyBPH and cMyBPC may be involved in autophagy. To test this hypothesis, both MyBPH and cMyBPC were analysed for co-localisation with a marker for autophagy, LC3b-II. The role of MyBPH and cMyBPC in cardiac cell contractility were analysed by measuring the planar cell surface area of differentiated H9c2 rat cardiomyocytes in response to β-adrenergic stress after individual and concurrent siRNA-mediated knockdown of MyBPH and cMyBPC. In the present study we employed a family-based genetic association analysis approach to investigate the contribution of genes encoding the novel MyBPH-interacting proteins in modifying the hypertrophy phenotype. This study investigated the hypertrophy modifying effects of 38 SNPs and haplotypes in four candidate HCM modifier genes, in 388 individuals from 27 HCM families, in which three unique South African HCM-causing founder mutations segregate. Yeast two-hybrid analysis identified three putative MyBPH-interacting proteins namely, cardiac β-myosin heavy chain (MYH7), cardiac α-actin (ACTC1) and the SUMO-conjugating enzyme UBC9 (UBC9). These interactions were verified using both 3D co-localisation and Co-IP analyses. Furthermore, MyBPH and cMyBPC were implicated in autophagy, since both these proteins were being recruited to the membrane of autophagosomes. In addition, a cardiac contractility assay demonstrated that the concurrent siRNA-mediated knockdown of MyBPH and cMyBPC resulted in a significant reduction in cardiomyocyte contractility, compared to individual protein and control knockdowns under conditions of β-adrenergic stress. These results indicated that MyBPH could compensate for cMyBPC, and vice versa, further confirming that both these proteins are required for efficient sarcomere contraction. Results from genetic association analyses found a number of SNPs and haplotypes that had a significant effect on HCM hypertrophy. Single SNP and haplotype analyses identified SNPs and haplotypes within genes encoding MyBPH, MYH7, ACTC1 and UBC9, which contribute to the extent of hypertrophy in HCM. In addition, we found that several variants and haplotypes had markedly different statistical significant effects in the presence of each of the three HCM founder mutations. The results of this study ascribe novel functions to MyBPH. Cardiac MyBPC and MyBPH play a critical role in sarcomere contraction and have been implicated in autophagy. This has further implications for understanding the patho-etiology of HCM-causing mutations in the gene encoding MyBPH and its interacting proteins. This is to our knowledge the first genetic association analysis to investigate the modifying effect of interactors of MyBPH, as indication of the risk for developing LVH in the context of HCM. Our findings suggest that the hypertrophic phenotype of HCM is modulated by the compound effect of a number of variants and haplotypes in MyBPH, and genes encoding protein interactors of MyBPH. These results provide a basis for future studies to investigate the risk profile of hypertrophy development in the context of HCM, which could consequently lead to improved risk stratification and patient management. / AFRIKAANSE OPSOMMING: Linker ventrikulêre hipertrofie (LVH) is 'n primêre risikofaktor vir kardiovaskulêre morbiditeit en mortaliteit asook 'n kenmerk van algemene siektes soos hipertensie en diabetes. Daarom is dit van kardinale belang om te verstaan wat die onderliggende meganismes is wat die ontwikkeling van LVH beïnvloed. Die ondersoek na die onderliggende meganismes wat lei tot LVH in sulke komplekse siektes is ‟n uitdaging. Om hierdie rede fokus baie navorsers hul aandag op die autosomaal dominante hartspier siekte, hipertrofiese kardiomiopatie (HKM), wat beskou word as 'n model siekte om die molekulêre oorsake onderliggend tot geïsoleerde kardiovaskulêre hipertrofie te ondersoek. HKM is 'n heterogene siekte wat manifesteer met verskeie fenotipes en kliniese simptome, selfs in families met dieselfde genetiese defekte, wat impliseer dat addisionele faktore bydra tot die modifisering van die siekte fenotipe. Ten spyte van die identifisering van verskeie HKM-versoorsakende gene, bly die genetiese faktore wat die mate van hipertrofie in HKM pasiente modifiseer relatief onbekend. Die geen wat kodeer vir die sarkomeriese proteïen, kardiale miosien-bindingsproteïen C (kMyBPC) is die algemeenste betrokke in HKM. Die identifisering van proteïene wat bind met kMyBPC het gelei tot verbeterde insigte tot die funksie van hierdie proteïen en die rol wat hierdie proteïen in hipertrofie speel. Ten spyte hiervan, is daar baie min inligting beskikbaar oor 'n ander lid van die miosien-bindingsproteïen families, miosien-bindingsproteïen H (MyBPH). Gegewe die ooreenstemming tussen die DNA basispaar-volgorde en struktuur tussen hierdie twee proteïene, stel ons voor dat MyBPH, net soos kMyBPC, 'n kritiese rol in die struktuur en funksie van die kardiale sarkomeer speel en kan daarom betrokke wees in die patogenese van HKM. Die huidige studie het beoog om proteïene wat met MyBPH bind te identifiseer deur die gebruik van gis-twee-hibried (G2H) kardiale biblioteek sifting en om hierdie interaksies te verifieer met behulp van drie-dimensionele (3D) ko-lokalisering en ko-immunopresipitasie eksperimente. Ons het verder gehipotiseer dat beide MyBPH and kMyBPC betrokke kan wees in outofagie. Om hierdie hipotese te toets is beide MyBPH en kMyBPC geanaliseer vir ko-lokalisering met 'n merker vir outofagie, LC3b-II. Verder het ons beplan om die rol van MyBPH en kMyBPC in kardiale spiersel-sametrekking te ondersoek deur die oppervlak van gedifferensieerde H9c2 rot kardiomiosiete in reaksie op β-adrenergiese stres te meet, na individuele en gesamentlike siRNA-bemiddelde uitklopping van MyBPH en kMyBPC. In hierdie studie het ons 'n familie-gebaseerde genetiese assosiasie analise benadering gevolg om vas te stel of MyBPH en gene wat kodeer vir die geverifieerde bindingsgenote van MyBPH bydra tot die modifisering van die hipertrofiese fenotipe. Die doel van hierdie studie was om die hipertrofiese effek van 38 enkel nukleotied polimorfismes (SNPs) en haplotipes in vier kandidaat HKM modifiserende gene in 388 individue van 27 HCM families te toets, waarin drie unieke Suid-Afrikaanse HKM-stigters mutasies segregeer. G2H analise het drie verneemde MyBPH bindingsgenote geidentifiseer, naamlik miosien (MYH7), alfa kardiale aktien (ACTC1) en die SUMO-konjugerende ensiem UBC9 (UBC9). Hierdie interaksies is geverifieer deur middel van 3D ko-lokalisering en ko-immunopresipitasie analises. Verder is bewys dat MyBPH en kMyBPC betrokke is in outofagie, siende dat beide proteïene gewerf is tot die membraan van die outofagosoom. 'n Kardiale sametrekkings eksperiment het gevind dat die gesamentlike siRNA-bemiddelde uitklopping van MyBPH en kMyBPC 'n merkwaardige vermindering in die kardiomiosiet sametrekking veroorsaak het in reaksie op β-adrenergiese stres kondisies, in vergelyking met die individuele proteïen en kontrole uitkloppings eksperimente. Hierdie resultate bevestig dat MyBPH vir kMyBPC kan instaan en ook andersom, wat verder bevestig dat beide proteïene benodig word vir effektiewe sarkomeer sametrekking. Resultate van die genetiese assosiasie studie het gevind dat 'n aantal SNPs en haplotipes 'n beduidende effek of HKM hipertrofie het. Enkel SNP en haplotipe analises in gene wat kodeer vir MyBPH, MYH7, ACTC1 en UBC9 het SNPs en haplotipes geidentifiseer wat bydra tot die omvang van hipertrofie in HKM. Verder het ons gevind dat sekere SNPs en haplotipes kenmerkend verskillende statisties beduidende effekte in die teenwoordigheid van elk van die drie HKM-stigter mutasies gehad het. Die resultate van hierdie studie skryf twee nuwe funksies aan MyBPH toe. Kardiale MyBPC en MyBPH speel 'n kritiese rol in sarkomeer sametrekking en is betrokke in outofagie. Hierdie resultate het verdere implikasies vir die verstaan van die pato-etiologie van die HKM-veroorsakende mutasies in die MyBPH, MYH7, ACTC1 en UBC9 gene. So vêr dit ons kennis strek is dit die eerste genetiese assosiasie studie wat die modifiserende effek van bindingsgenote van MyBPH ondersoek as risiko aanduiding vir die ontwikkeling van LVH in die konteks van HKM. Ons bevindinge bewys dat die hipertrofiese fenotipe van HKM gemoduleer word deur die komplekse effekte van SNPs en haplotipes in die MyBPH geen en gene wat MyBPH proteïen-bindingsgenote enkodeer. Hierdie resultate verskaf dus 'n basis vir toekomstige studies om die risiko profiel van hipertrofie ontwikkeling met betrekking tot HKM te ondersoek, wat gevolglik kan bydra tot die verbeterde risiko stratifikasie en pasiënte bestuur.

Bien que les progrès thérapeutiques aient permis de freiner la progression des maladies cardio-vasculaires (CV), mais surtout d'améliorer leur prévention et par conséquent de réduire la survenue d'accidents CV, ces maladies devraient rester les premières causes mondiales de décès dans les prochaines années. Cet état des lieux épidémiologique illustre donc des insuffisances concernant à la fois la prévention, mais également la prise en charge du risque CV. Ce travail de thèse s'est alors intéressé à la compréhension des mécanismes physiopathologiques de l'insuffisance cardiaque ischémique (ICi), maladie CV la plus répandue, afin de proposer des stratégies préventives limitant le remodelage cardiaque délétère ; ainsi qu'à l'étude de la pollution atmosphérique comme potentiel facteur de risque CV. Le couplage excitation-métabolisme-contraction (E-M-C), qui sous-tend la fonction de la pompe cardiaque, s'adapte en réponse à différents stimuli par une modification des interrelations spatiales et temporelles complexes entre activités électriques, énergétiques et mécaniques. Ces modifications à différents niveaux peuvent initier un remodelage délétère évoluant vers une altération du fonctionnement, voire une défaillance chronique, du myocarde.Ce travail de thèse met en évidence un découplage entre les activités mitochondriales et contractiles, à l'origine d'un déséquilibre des homéostasies ioniques et redox, responsables des dysfonctions cardiaques étudiées dans des contextes d'ICi et d'exposition en milieu pollué au CO. Ainsi, une approche thérapeutique, visant à restaurer les fonctions mitochondriales et à rétablir le couplage E-M-C cardiaque, pourrait être considérée afin de préserver au mieux la fonction myocardique. Ce travail de thèse permet alors une meilleure compréhension des mécanismes physiopathologiques de l'ICi, et identifie la pollution atmosphérique comme facteur de risque CV à considérer en clinique afin de mieux prévenir le risque CV. / Abstract non available.

Durant le développement myocardique, les cardiomyocytes s'allongent et se connectent entre eux grâce à une structure spécialisée, le disque intercalaire. Cette organisation des cardiomyocytes est essentielle pour le couplage mécanique et la conduction électrique. Un des éléments responsables de l'insuffisance cardiaque est la perturbation de ces sites de contact intercellulaire. Actuellement, aucun facteur n'est connu pour coordonner l'organisation polarisée des cardiomyocytes. Ici, nous présentons une augmentation importante de Pdzrn3 dans des cardiomyopathies hypertrophiques humaines et dans des myocardes murins, corrélée à une perte de l'élongation polarisée des cardiomyocytes. De plus la délétion spécifique intramyocardique de l'expression de Pdzrn3, dans un modèle murin, protège de la survenue d'une insuffisance cardiaque secondaire à une cardiomyopathie hypertrophique. Nos résultats révèlent une nouvelle voie de signalisation qui contrôle un programme génétique essentiel pour le développement myocardique, le maintien de la géométrie et de la fonction contractile des cardiomyocytes. Cette voie de signalisation implique PDZRN3 et cette molécule constitue une cible thérapeutique potentielle pour la protection de l’insuffisance cardiaque chez l’homme. / During heart maturation, individual cardiomyocytes stretch out and connect some with the others via their extremities by intercalated disk protein complexes. This planar and directionnel organization of the myocyte sis crucial for the machanical coupling and the anisotropic conduction of the electric signal in the heart. One of the hallmarks of heart failure concerns alterations in the contact sites between cardiomyocytes. Yet no factors on its own is known to coordinate cardiomyocyte polarized organization. Here we reported enhanced levels of Pdzrn3 in the diseased hypertrophic human and mouse myocardium, correlated with the loss of cardiomyocyte polarized elongation. Furthermore, mouse cardiac Pdzrn3 deficiency protected against heart failure in a mouse model of hypertrophic cardiomyopathy. Our results reveal a novel signaling that controls a genetic program essential for heart maturation and for maintain of cardiomyocyte overall geometry and contractile function and implicates PDZRN3 as a potential therapeutic target for human heart failure protection.

Vários aspectos fisiopatogênicos da cardiomiopatia chagásica crônica (CCC) ainda carecem de elucidação, principalmente os mecanismos que determinam o aparecimento da lesão miocárdica crônica apenas em fase bastante tardia, 2 a 3 décadas após a fase aguda da doença. Evidências experimentais e clínicas apontam para uma participação da isquemia microvascular neste processo lento de progressão da cardiomiopatia. Defeitos de perfusão miocárdica (DP) são frequentes na CCC, mas as alterações teciduais associadas e seu significado fisiopatológico ainda não são claros. Neste cenário, o emprego do modelo experimental em hamster que reproduz a fase crônica da CCC após 6 meses da infecção, poderia fornecer observações valiosas sobre esses mecanismos fisiopatogênicos. Dessa forma, o presente estudo objetivou empregar imagens in vivo para investigar a correlação entre as alterações de perfusão com a gravidade da disfunção miocárdica na CCC assim como as alterações histopatológicas subjacentes em modelo experimental em hamsters. Para tanto, hamsters sírios fêmeas (n=60) foram infectados com 3,5x 104 ou 105 formas tripomastigotas sanguíneas de T. cruzi (cepa Y) enquanto um grupo de animais (n=8) recebeu inóculo de salina. Os animais foram investigados após 6 ou 10 meses de infecção, empregando-se imagens in vivo da perfusão miocárdica com SPECT-Sestamibi-Tc99m de alta resolução e da função sistólica segmentar e global do ventrículo esquerdo (VE) com Ecocardiograma 2D. Procedeu-se à análise histológica para quantificação regional de intensidade de inflamação, extensão de fibrose e densidade microvascular. Utilizou-se segmentação do VE em 13 segmentos para todos os métodos de análise. Dos 34 animais infectados que sobreviveram ao final do estudo, 10 (29%) apresentaram fração de ejeção (FE) reduzida (48,5±11,4%) em relação aos controles (82,4±5,5%), p<0,0001. Entre os 24 animais com FE preservada (82,9±5,5%, p>0,05 em comparação ao controle), 8 (33%) apresentavam alterações de mobilidade parietal segmentar (MPS) que predominaram nos segmentos apicais, inferiores e póstero-laterais. Os animais com FE rebaixada apresentaram maior intensidade de inflamação quando comparados a todos os outros animais, maior extensão de fibrose somente quando comparados aos animais controles, mas semelhante densidade microvascular. O escore de MPS correlacionou-se com a FE (r=-0,60; p=0,0002), com a inflamação (r=0,53 - p=0,0014), mas não exibiu correlação com a fibrose (r=0,25 - p=0,16) e densidade microvascular (r=0,24; p=0,17). Defeitos perfusionais (DP) estavam presentes em 17 (50%) dos animais infectados e não apresentaram correlação topográfica com fibrose transmural. Os animais com perfusão alterada, quando comparados aos animais sem DP, exibiram menor FE (65±21 e 81±9%, p<0,01), maior inflamação (172,8±89 e 111,5±54n/mm²; p=0,04), maior escore de MPS (1,44±0,5 e 1,04±0,05; p=0,003), mas semelhante extensão de fibrose (8,4±3,9; 6,6±3,2%/mm2; p=0,06) e densidade dos vasos da microcirculação (0,69±0,5 e 0,57±0,2%/mm2; p= 0,6). Observou-se associação topográfica significativa entre presença de DP e alteração de MPS (p<0,01). De todos os segmentos analisados (n=438), aqueles exibindo alteração de MPS em comparação aos com MPS normal, apresentaram maior fibrose (9,34±5,7 e 7±6,3%/mm2, p<0,0001); maior inflamação (218±111,6 e 124,5±84,8n/mm², p<0,0001), mas semelhante densidade de microvasos (0,72±0,66 e 0,62±0,38%/mm2, p=0,89). Os segmentos com DP quando comparados aos segmentos sem defeitos mostraram maior inflamação (175,8±145; 111,6±69,2n/mm²; p=0,001), maior escore de MPS (1,65±0,6; 1,1±0,4; p<0,0001), entretanto com semelhante extensão de fibrose (10,5±18,6; 7,4±6,2%/mm2; p=0,37) e de densidade microvascular (0,72±0,64; 0,63±0,5%/mm2; p=0,38). Os resultados mostram que as alterações da MPS são frequentes, ocorrendo em animais com desempenho global ainda preservado. Os DP em CCC são topograficamente correlacionados a alterações inflamatórias que são intensas o suficiente para promover disfunção sistólica regional e global do VE. O fato destes distúrbios não serem devidos à fibrose transmural abre a possibilidade de que as intervenções terapêuticas destinadas a reduzir o grau de inflamação do miocárdio e/ou da hipoperfusão possam se acompanhar de recuperação da função sistólica cardíaca e impactar favoravelmente na história natural da CCC. / Several pathophysiological aspects of chronic Chagas cardiomyopathy still need elucidation, specially the mechanisms that determine the development of chronic myocardial injury, 2-3 decades after the acute phase of the disease. Experimental and clinical evidence suggest the participation of microvascular ischemia in this slow progression of cardiomyopathy. Myocardial perfusion defects (PD) are frequent in CCC, but its underlying tissue changes and pathophysiologic mechanisms are unclear. In this scenario, the use of experimental hamster model that reproduces the chronic phase of the CCC after 6 months of infection, would provide valuable insights into the pathophysiological mechanisms. Therefore, the present study aimed to employ in vivo images to investigate the presence of perfusion changes and its correlation with left ventricular systolic dysfunction and underlying histopathological changes in an experimental model in hamsters. For this purpose, female Syrian hamsters (n=60) were infected with 3,5x 104 or 105 trypomastigotes forms of T. cruzi (Y-strain) while a group of animals (n=8) has received saline inoculum. The animals were investigated after 6 or 10 months infection, employing in vivo high-resolution Sestamibi-Tc-99m-SPECT imaging of myocardial perfusion and segmental and global systolic function of the left ventricle (LV) with 2D echocardiography. Histological analysis was performed to quantify regional intensity inflammation, extension of fibrosis and microvascular density. Were used 13 segments for LV segmentation for all imaging methods. Among the 34 infected animals who survived at the end of the study, 10 (29%) showed reduced ejection fraction (EF) (48,5±11,4%) compared to controls (82,4±5,5%), p<0,0001. Among the 24 animals with preserved EF (82,9±5,5%, p>0,05 compared to controls), 8 (33%) showed abnormal segmental wall motion (SWM) that predominated in the apical, inferior and posterolateral. Animals with reduced EF showed more intensive inflammation compared to other animals, greater extension of fibrosis only when compared to controls, but similar microvascular density. The score of SWM correlated with the EF (r=-0,60; p=0,0002), with inflammation (r=0,53 - p=0,0014), but showed no correlation with fibrosis (r=0,25 - p=0,16) and microvascular density (r=0,24; p=0,17). PD were present in 17 (50%) infected animals and showed no topographic correlation with transmural scar. Animals with altered perfusion, compared to animals without PD, exhibited lower EF (65±21 and 81±9%, p<0,01), more intense inflammation (172,8±89 and 111,5±54n/mm²; p=0,04), higher score of SWM (1,44±0,5 and 1,04±0,05; p=0,003), but similar extension of fibrosis (8,4±3,9; 6,6±3,2%/mm2; p=0,06) and microvascular density (0,69±0,5 and 0,57±0,2%/mm2; p= 0,6). There was significant topographic association between the presence of PD and abnormal SWM (p<0,01). Of all segments analyzed (n=438), those showing change in SWM compared with the normal SWM, showed more fibrosis (9,34±5,7 and 7±6,3%/mm2, p<0,0001); more intense inflammation (218±111,6 and 124,5±84,8n/mm², p<0,0001), but similar microvascular density (0,72±0,66 and 0,62±0,38%/mm2, p=0,89). The segments with PD compared to segments without defects showed more intense inflammation (175,8±145; 111,6±69,2n/mm²; p=0,001), higher score of SWM (1,65±0,6; 1,1±0,4; p<0,0001), however with similar extension of fibrosis (10,5±18,6; 7,4±6,2%/mm2; p=0,37) and microvascular density (0,72±0,64; 0,63±0,5%/mm2; p=0,38). The results show that changes in SWM are frequent, occurring in animals with global performance still preserved. The PD in experimental CCC are topographically correlated with inflammatory changes that are intense enough to enough to cause wall motion impairment. The fact that these derangements are not due to fibrosis opens the possibility that therapeutic interventions aimed at reducing the degree of myocardial inflammation and/or hypoperfusion may favorably impact on the natural history of this model of experimental CCC.